Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680377 · ClinicalTrials.gov registry record
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
A clinical trial of NSCLC, Stage III and Locally Advanced Lung Carcinoma, sponsored by Jun Zhang, MD, PhD.
- Recruiting
- Registry status
- 44
- Enrollment target
- 2
- Study locations
NCT04680377 is a study of NSCLC, Stage III and Locally Advanced Lung Carcinoma that is actively recruiting participants, run by Jun Zhang, MD, PhD. The registered enrollment target is 44 participants, roughly in line with the 43-participant average among 3 other NSCLC, Stage III trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT04680377, a study of NSCLC, Stage III and Locally Advanced Lung Carcinoma, is actively recruiting participants, sponsored by Jun Zhang, MD, PhD.
- RECRUITING
- Registry status
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Conditions Studied
Study Locations (2)
Kansas
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
Rhode Island
- Rhode Island Hospital, Brown University - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04680377
The ClinicalTrials.gov registry entry for NCT04680377 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 43-participant average among 3 other NSCLC, Stage III trials with a reported enrollment target. The listed sponsor is Jun Zhang, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NSCLC, Stage III appearing as the primary indexed condition, and to 0 interventions.
NCT04680377 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04680377 about?
NCT04680377 is a clinical study titled "Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients". This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
What is the current status of trial NCT04680377?
This trial is currently recruiting. The enrollment target is 44 participants. The study started on 2021-04-12. Estimated completion is 2026-12.
What conditions does trial NCT04680377 study?
This clinical trial studies the following conditions: NSCLC, Stage III, Locally Advanced Lung Carcinoma.
Who is sponsoring clinical trial NCT04680377?
This trial is sponsored by Jun Zhang, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04680377 being conducted?
This trial has 2 study locations across Kansas, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC, Stage III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
RECRUITING · Phase 3
-
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
RECRUITING · NA
-
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.